LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. plc (NASDAQ: AMRN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AMRN as the Company's latest news hit the wire. On January 17, 2018, the Company, a biopharmaceutical organization focused on the commercialization and development of therapeutics to improve cardiovascular health, declared that its partner Eddingpharm has initiated the clinical trial of Vascepa (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia (TG ≥500 mg/dL) in Mainland China, or China. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Amarin most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=AMRN
About Vascepa
Amarin's first FDA approved product, Vascepa, is a highly pure, omega-3 fatty acid, which is available by prescription. Vascepa capsules, known as AMR101 in scientific literature, are single-molecule prescription products that contain omega-3 acid EPA in ethyl-ester form. Vascepa is known to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels.
Although Vascepa is not fish oil, it is derived from fish through a stringent and complex FDA-regulated manufacturing process of eliminating impurities and isolating and protecting the single molecule active ingredient.
Amarin Signed Exclusive Agreement with Eddingpharm for Vascepa
On February 26, 2015, Amarin signed an exclusive agreement with Eddingpharm to develop and commercialize Vascepa in Mainland China, Hong Kong and Macao Special Administrative Regions, and Taiwan. As per the agreement, Eddingpharm is responsible for Vascepa's development, regulatory activities, commercialization, and its associated costs.
Eddingpharm is a Chinese specialty pharmaceutical Company dedicated towards bringing high-quality medicines from all over the world to the Chinese healthcare market in order to provide patients with more treatment options and better healthcare opportunities. The Company has a strong footprint in top-tier cities of China, while it is growing rapidly in lower tier cities. It has over 17,000 hospitals and 15,000 pharmacies in 30 provinces with a sales force of over 1,000 professional personnel. Over the years, Eddingpharm has expanded its product portfolio through in-licensing, joint ventures, strategic alliances, exclusive distribution, and other forms of collaboration with multinational pharmaceutical Companies, specialty pharmaceutical Companies, and biotech Companies in the US and Europe.
Vascepa's Success in MARINE Trial
The MARINE trial was a Phase-3, multi-center, placebo-controlled, randomized, double-blind, 12-week study that treated patients with severe (≥500 mg/dL) hypertriglyceridemia, more commonly known as very high triglycerides, or VHTG. It enrolled a total of 229 patients.
Amarin reported positive top-line results for the MARINE trial in November 2010, which met its primary and other key efficacy endpoints. The MARINE trial showed that Vascepa 4g/day considerably decreased triglyceride levels by 33% compared to placebo, without increasing LDL-C (non-significant decrease of 2% vs placebo). Moreover, Vascepa also exhibited a statistically significant decrease compared to placebo in multiple other important lipid biomarkers in MARINE, including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apo B), lipoprotein-phospholipase A2 (Lp-PLA2), very low-density lipoprotein cholesterol (VLDL-C), total cholesterol (TC), and the inflammatory marker high-sensitivity C-reactive protein (hsCRP).
New Trial to Evaluate Vascepa in China
Eddingpharm intends to conduct a multi-center, placebo-controlled, randomized, double blind trial in China, similar to the MARINE trial conducted by Amarin. It would be a 12-week study on patients with severe hypertriglyceridemia, more commonly known as very high triglycerides, or VHTG. Its primary endpoint is the percentage change in triglyceride levels from baseline compared to placebo after 12 weeks of treatment. Eddingpharm expects this study to complete within the next two years.
This clinical trial could make Vascepa the first-ever pure prescription grade EPA-based drug product in China. However, its commercial opportunity in China is mostly based on the prevalence of hypertriglyceridemia in the country. It is estimated that hypertriglyceridemia affects approximately 17.7% of the adult Chinese population, which is about 185 million people.
Stock Performance Snapshot
January 18, 2018 - At Thursday's closing bell, Amarin's stock marginally dropped 0.50%, ending the trading session at $3.98.
Volume traded for the day: 1.29 million shares.
Stock performance in the last month – up 17.40%; previous three-month period – up 20.97%; and past twelve-month period – up 36.30%
After yesterday's close, Amarin's market cap was at $1.03 billion.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Other industry. This sector was flat at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
